Relmada Therapeutics Inc (RLMD)

Mar 30, 2025

Relmada outlines plans for NDV-01 Phase 2 results presentation and sepranolone development - MSN

Mar 30, 2025

Mar 29, 2025

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025

Mar 28, 2025

Relmada Therapeutics: Strategic Acquisitions and Pipeline Progress - TipRanks

Mar 28, 2025

Mar 28, 2025

Relmada Therapeutics pivots from psilocybin to cancer, neurological disorders - Green Market Report

Mar 28, 2025

Mar 28, 2025

Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... - Yahoo Finance

Mar 28, 2025

Mar 28, 2025

Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights - GuruFocus

Mar 28, 2025

Mar 27, 2025

Relmada Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks

Mar 27, 2025

Mar 27, 2025

Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS - Investing.com India

Mar 27, 2025

Mar 27, 2025

RELMADA THERAPEUTICS Earnings Results: $RLMD Reports Quarterly Earnings - Nasdaq

Mar 27, 2025

Mar 27, 2025

Relmada Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025

Mar 27, 2025

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - The Manila Times

Mar 27, 2025

Mar 27, 2025

Relmada Cuts Losses by 25%: Key Pipeline Programs Hit Critical Phase in 2025 - Stock Titan

Mar 27, 2025

Mar 26, 2025

Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone PharmaSEC Filing - MarketScreener

Mar 26, 2025

Mar 26, 2025

Insights Ahead: Relmada Therapeutics's Quarterly Earnings - Benzinga

Mar 26, 2025

Mar 26, 2025

Mizuho maintains Relmada stock neutral with $1.00 target By Investing.com - Investing.com Canada

Mar 26, 2025

Mar 26, 2025

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 - Quantisnow

Mar 26, 2025

Mar 26, 2025

Mizuho maintains Relmada stock neutral with $1.00 target - Investing.com India

Mar 26, 2025

Mar 26, 2025

Mizuho Reiterates Neutral Rating on Relmada Therapeutics Inc (RLMD) - StreetInsider.com

Mar 26, 2025

Mar 25, 2025

Relmada secures exclusive license for potential bladder cancer therapy By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - Quantisnow

Mar 25, 2025

Mar 25, 2025

Relmada secures exclusive license for potential bladder cancer therapy - Investing.com India

Mar 25, 2025

Mar 25, 2025

Relmada Therapeutics Announces Exclusive Licensing Agreement for NDV-01, a Novel Intravesical Therapy for Non-Muscle Invasive Bladder Cancer - Nasdaq

Mar 25, 2025

Mar 25, 2025

Relmada Therapeutics (RLMD) Licenses NDV-01 from Trigone Pharma - StreetInsider.com

Mar 25, 2025

Mar 25, 2025

Game-Changing Cancer Drug: Relmada's New Treatment Lasts 10 Days vs Hours - Stock Titan

Mar 25, 2025

Mar 23, 2025

RELMADA THERAPEUTICS Earnings Preview: Recent $RLMD Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 23, 2025

Mar 14, 2025

Relmada Therapeutics Inc expected to post a loss of 70 cents a shareEarnings Preview - TradingView

Mar 14, 2025

Mar 11, 2025

Relmada Therapeutics (RLMD) Projected to Post Earnings on Tuesday - Defense World

Mar 11, 2025

Mar 03, 2025

Relmada seeking strategic options, stock climbs 5% - MSN

Mar 03, 2025

Mar 03, 2025

RELMADA THERAPEUTICS, INC. INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Relmada Therapeutics, Inc. - ACCESS Newswire

Mar 03, 2025

Feb 25, 2025

Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.

Feb 25, 2025

Feb 24, 2025

RLMD stock touches 52-week low at $0.28 amid market challenges - Investing.com Australia

Feb 24, 2025

Feb 24, 2025

RLMD stock touches 52-week low at $0.28 amid market challenges By Investing.com - Investing.com South Africa

Feb 24, 2025

Feb 19, 2025

A significant driver of top-line growth: Relmada Therapeutics Inc (RLMD) - SETE News

Feb 19, 2025

Feb 16, 2025

Relmada acquires new Tourette syndrome treatment asset - MSN

Feb 16, 2025

Feb 11, 2025

Relmada Therapeutics Inc [RLMD] Investment Guide: What You Need to Know - Knox Daily

Feb 11, 2025

Feb 10, 2025

RLMD stock’s current quarter earnings estimates: What analysts predict? - US Post News

Feb 10, 2025

Feb 10, 2025

Closing Strong: Relmada Therapeutics Inc (RLMD) Ends at 0.31, Down -9.62 from Last Close - The Dwinnex

Feb 10, 2025

Feb 10, 2025

Relmada Therapeutics Inc’s Shares Reel: -90.69% Quarterly Revenue Decline Amid 9.33M Market Cap - The InvestChronicle

Feb 10, 2025

Feb 07, 2025

A company insider recently bought 51,407 shares of Relmada Therapeutics Inc [RLMD]. Should You Buy? - Knox Daily

Feb 07, 2025

Feb 07, 2025

Mizuho maintains Neutral on Relmada stock, sees deal potential - MSN

Feb 07, 2025

Feb 07, 2025

The Tourette’s Deal That Came Too Late To Save Sweden’s Asarina - Insights

Feb 07, 2025

Feb 07, 2025

Relmada in-licenses Tourette syndrome drug from Asarina - The Pharma Letter

Feb 07, 2025

Feb 07, 2025

Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - SETE News

Feb 07, 2025

Feb 07, 2025

Relmada acquires Tourette’s therapy rights from Asarina - Yahoo Finance

Feb 07, 2025

Feb 07, 2025

Lipella Pharmaceuticals Inc [LIPO] Revenue clocked in at $0.48 million, up 52.46% YTD: What’s Next? - The DBT News

Feb 07, 2025

Feb 07, 2025

Relmada acquires new Tourette syndrome treatment asset By Investing.com - Investing.com Nigeria

Feb 07, 2025

Feb 06, 2025

Mizuho maintains Neutral on Relmada stock, sees deal potential By Investing.com - Investing.com Australia

Feb 06, 2025